LSU Health New Orleans joins COVID-19 treatment clinical trial at UMC


LSU Health New Orleans joins a National Institutes of Health clinical trial to test the safety and effectiveness of a potential new COVID-19 treatment.

Professor and Pulmonary/Critical Care specialist at LSU Health New Orleans School of Medicine, Dr. Bennett deBoisblanc, is the principal investigator at the University Medical Center clinical trial site.

The phase-3 monoclonal antibody trial is one of four clinical trials testing multiple different coronavirus treatments under the NIH’s Therapeutic Interventions and Vaccines program.

Researchers are looking for approximately 300 volunteer patients to enroll in the clinical trial.

"Patients hospitalized with mild to moderate COVID-19 with fewer than 13 days of symptoms may volunteer to participate,” according to an LSU Health New Orleans press release. “Once their COVID-19 infections have been confirmed and they have consented to take part in the study, participants will be randomly assigned to receive either an intravenous (IV) infusion of the monoclonal antibody, LY-CoV555, or a saline placebo infusion. Participants also will receive standard care for COVID-19, including the antiviral Remdesivir. After five days, participants’ symptoms will be assessed, as will their need for supplemental oxygen, mechanical ventilation, or other supportive care. Volunteers will be followed for 90 days after enrollment and will receive regular examinations and have blood samples taken periodically during this time to analyze their response to the investigational therapeutic."

If results in the trial appear to be safe and effective, then an additional 700 volunteer patients will be asked to enroll.

 “Clinical trials like ACTIV-3 will help determine effective treatments for COVID-19, something we desperately need,” notes Dr. deBoisblanc. “We are grateful to the NIH for selecting LSU Health and UMC to participate in this critically important research.”

More information about the ACTIV-3 clinical trial is available here.